A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Inclusion Criteria:

- Male or female, aged 18-75 years (both inclusive) at the time of signing informed
consent

- Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the
day of screening

- HbA1c of 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central laboratory

- Stable daily dose(s) for 90 days prior to the day of screening of any of the following
antidiabetic drug(s) or combination regime(s): Any metformin formulations greater than
or equal to 1500 mg or maximum tolerated or effective dose (as documented in subject's
medical record) OR Any metformin formulations greater than or equal to 1500 mg or
maximum tolerated or effective dose (as documented in subject medical record) with
Dipeptidyl peptidase-4 inhibitor (DPP4i) (greater than or equal to half of the maximum
approved dose according to local label or maximum tolerated or effective dose (as
documented in subject's medical records)

- Insulin naïve. However, short term insulin treatment for a maximum of 14 days prior to
the day of screening is allowed, as is prior insulin treatment for gestational
diabetes

- Body mass index (BMI) less than or equal to 40.0 kg/m^2

Exclusion Criteria:

- Any episodes of diabetic ketoacidosis within the past 90 days prior to the day of
screening and between screening and randomisation

- Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or
transient ischaemic attack within 180 days prior to the day of screening and between
screening and randomisation

- Presently classified as being in New York Heart Association (NYHA) Class IV

- Treatment with any medication for the indication of diabetes or obesity other than
stated in the inclusion criteria within the past 90 days prior to the day of
screening. However, short term insulin treatment for a maximum of 14 days prior to the
day of screening is allowed, as is prior insulin treatment for gestational diabetes

- Anticipated initiation or change in concomitant medications (for more than 14
consecutive days) known to affect weight or glucose metabolism (e.g. treatment with
orlistat, thyroid hormones, or corticosteroids)

- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by
a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist
or another suitably qualified health care provider within the past 90 days prior to
screening or in the period between screening and randomisation